MMRC research efforts are selected and overseen by a dynamic team of experts in the field of multiple myeloma, including representation from world-renowned MMRC Member Institutions as well as key leadership from the Multiple Myeloma Research Foundation. This multidisciplinary team, with expertise in the fields of multiple myeloma research, clinical care, and executive leadership, provides both strategic direction and scientific oversight to the Consortium.

		Kenneth Anderson, MD - Chair Chief, Division of Hematologic Neoplasia Director, Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute Dr. Anderson graduated from Johns Hopkins Medical School. He trained in internal medicine at Johns Hopkins Hospital and completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School and serves as Chief of the Division of Hematologic Neoplasia, Director of the Jerome Lipper Multiple Myeloma Center, and Vice Chair of the Joint Program in Transfusion Medicine at the Dana-Farber Cancer Institute. He received the Waldenstrom's Award in 2003 for his translational research directed to the development of novel therapeutics targeting the myeloma cell in its microenvironment. He serves as Chair of the National Comprehensive Cancer Network's Multiple Myeloma Clinical Practice Guidelines Committee, on the Board of Directors and as Chairman of the Scientific Advisors of the Multiple Myeloma Research Foundation, and is a Doris Duke Distinguished Clinical Research Scientist
		Shaji Kumar
		Andrzej Jakubowiak, MD, PhD University of Michigan Andrzej Jakubowiak received both his medical and doctoral degrees from the Medical Academy in Pozan, Poland. Prior to joining the faculty of the University of Michigan in 2000, Dr. Jakubowiak completed a fellowship in hematology/oncology from Memorial Sloan-Kettering Cancer Center in New York. His clinical interests are in the treatment of multiple myeloma and other hematological malignancies including Hodgkin’s and non-Hodgkin’s lymphoma, and acute/chronic leukemia. Dr. Jakubowiak’s research focuses on treatment protocols for multiple myeloma and lymphoma.
		Sagar Lonial, MD Associate Professor of Medicine Emory University Dr. Lonial completed his Hematology-Oncology training at Emory University, and prior to that completed his internal medicine residency at the Baylor College of Medicine in Houston, Texas. Dr. Lonial is an Assistant Professor at the Winship Cancer Institute of Emory University, and is also Director of Translational Research, B-cell malignancy program. Dr. Lonial has worked in the field of immunotherapy and cancer since his arrival at Emory, and in the previous years has spent time developing the B-cell malignancy program with respect to novel targeted agents in laboratory models as well as early clinical trials. Dr. Lonial’s laboratory work has focused on evaluating the impact of purified dendritic cell subsets on the nature of immune responses against antigen. Most recently Dr. Lonial has focused on combinations of novel agents as therapy for myeloma and lymphoma.